Surgical waiting times in patients with high‐ and low‐risk renal cell carcinoma in England
Authors:
- Raghav VarmaRVRaghav Varma
- Emily MayneEMEmily Mayne
- Will CuninghamWCWill Cuningham
- Marina A. ParryMPMarina A. Parry
- Arjun NathanANArjun Nathan
- Adrian CookACAdrian Cook
- Maxine G. B. TranMTMaxine G. B. Tran
- James M. DouglasJDJames M. Douglas
- Axel BexABAxel Bex
- Jan van der MeulenJMJan van der Meulen
- Amit BahlABAmit Bahl
Open Access
- 11 October 2026
- journal article
- research article
- Published by Wiley in BJU International
Abstract
Objectives: To assess to what extent hospitals meet the uniform English National Health Service ‘timely’ treatment standard, what happens after a breach, and determinants of delay for patients with high‐risk renal cell carcinoma (RCC). Patient and Methods: Population‐based study using linked data for 7030 patients with high‐risk and 10 708 patients with low‐risk RCC, 2019–2023. The probabilities of ‘timely’ treatment and prolonged delay (≤31 days or >62 days from decision‐to‐treat, respectively) were estimated using multilevel logistic regression. Daily treatment probabilities beyond 31 days were represented using smoothed hazard rates. Results: For a typical patient with high‐risk RCC, timely treatment declined from 83.7% (2019) to 64.8% (2023), with a corresponding decline in the low‐risk group from 71.3% to 47.6%, while prolonged delays more than doubled, from 3.9% to 9.4%. Patients with high‐risk RCC were prioritised over those with low‐risk disease (73.6% vs 58.2%; adjusted risk ratio 1.26, 95% confidence interval 1.22–1.31). Older and more socioeconomically deprived patients experienced longer delays. Once the standard was breached, the daily probability of surgery declined sharply. Adjusted percentages of patients with high‐ and low‐risk RCC treated within the standard were strongly correlated ( r = 0.78). Conclusion: Prioritisation of patients with high‐risk RCC was maintained throughout the study period but did not prevent a system‐wide decline in timely treatment. Patients who breach the timely treatment standard face diminishing daily probabilities of surgery. Risk‐stratified standards, ring‐fenced surgical capacity, and monitoring beyond defined timely treatment standards are needed to safeguard patients against delays that have significant prognostic implications.Keywords
This publication has 20 references indexed in Scilit:
- Percutaneous thermal ablation versus robot-assisted partial nephrectomy for localized renal cell carcinoma: a systematic review and meta-analysis stratified by tumor complexityJournal of Robotic Surgery, 2026
- Comparing the national cancer waiting times dataset with other linked electronic health records to measure treatment timeliness: A national cohort study of kidney cancer in EnglandCancer Epidemiology, 2026
- UK cancer care: a watershed moment and the need for urgent interventionThe Lancet Oncology, 2022
- European Groundshot—addressing Europe's cancer research challenges: a Lancet Oncology CommissionThe Lancet Oncology, 2022
- Upstaging to pT3a in Patients Undergoing Partial or Radical Nephrectomy for cT1 Renal Tumors: A Systematic Review and Meta-analysis of Outcomes and Predictive FactorsEuropean Urology Focus, 2021
- Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based studyThe Lancet Oncology, 2019
- Counting the cost of cancelled surgery: a system wide approach is neededBritish Journal of Anaesthesia, 2018
- Active Surveillance of Small Renal Masses: Progression Patterns of Early Stage Kidney CancerEuropean Urology, 2011
- Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson ScoreBritish Journal of Surgery, 2010
- Survival Analysis2003